SLDB on XNAS, Health Care, Solid Biosciences Inc., job postings
Measures activity, not value. Not investment advice.
Short interest of 17.1M shares is 1.7 times a year earlier while stock is up 40% in 12 months.
BadFree cash flow was negative $200.3M over 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Industry
Biological products, (no diagnostic substances) (Health Care)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $53.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $56.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$53.9M
30 Jun 2026
–
-$54.8M
31 Mar 2026
–
-$56.7M
31 Dec 2025
–
-$49.8M
30 Sep 2025
–
-$45.8M
30 Jun 2025
–
-$39.5M
31 Mar 2025
–
-$39.3M
31 Dec 2024
–
-$42.6M
30 Sep 2024
–
-$32.7M
30 Jun 2024
–
-$25.1M
31 Mar 2024
–
-$24.3M
31 Dec 2023
–
-$20.3M
30 Sep 2023
–
-$21.0M
30 Jun 2023
–
-$24.6M
31 Mar 2023
–
-$30.1M
31 Dec 2022
–
-$15.2M
30 Sep 2022
–
-$20.4M
30 Jun 2022
–
-$25.1M
31 Mar 2022
–
-$25.3M
31 Dec 2021
–
-$18.6M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$215.3M
-$167.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.79
-$2.51
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-76.9%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$200.3M
-$133.2M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$348.9M
$236.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$3.07
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.0
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$25K
bought $0, sold $25K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-0.6%
156 13F filers vs 157
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
118.8M shares held by 13F filers (30 Sep 2026) of 111.6M outstanding (30 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
12%
13.3M shares sold short (30 Oct 2026) of 111.6M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
10.7
13.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+8.2%
12.3M shares sold short in the report before, 13.3M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
71%
71% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
14
14 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
14×
14 articles in the last 7 days; its usual week has 1.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 17.1M, 1.7× a year earlier
Price $6.25 on 20 Nov 2026, +40% over 12 months (12-month range $4.46 to $11.15)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $2.7M in the last 12 months (the 12 months before: $25.8M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 4 published in the last 12 months, +33% on the 12 months before.Capital spending per quarter. Capital spending $498K in the latest quarter, +486% on a year earlier.Institutional holders (13F filers). 156 13F filers reported holding it in the latest 13F quarter, +25% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $660K, +1000% on a year earlier; public on 15 Mar 2022
Quarter ended 31 Mar 2022: $184K, +426% on a year earlier; public on 28 Apr 2022
Quarter ended 30 Jun 2022: $1.1M, +226% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $839K, +254% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $856K, +30% on a year earlier; public on 24 Mar 2023
Quarter ended 31 Mar 2023: $506K, +175% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $536K, -53% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $383K, -54% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $90K, -89% on a year earlier; public on 14 Mar 2024
Quarter ended 31 Mar 2024: $149K, -71% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $286K, -47% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $15K, -96% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $204K, +127% on a year earlier; public on 7 Mar 2025
Quarter ended 31 Mar 2025: $126K, -15% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $377K, +32% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $85K, +467% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $565K, +177% on a year earlier; public on 20 Mar 2026
Quarter ended 31 Mar 2026: $165K, +31% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $150K, -60% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $498K, +486% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 78; public on 14 Feb 2022
31 Mar 2022 report: 74; public on 16 May 2022
30 Jun 2022 report: 65; public on 15 Aug 2022
30 Sep 2022 report: 56; public on 14 Nov 2022
31 Dec 2022 report: 36; public on 14 Feb 2023
31 Mar 2023 report: 37; public on 15 May 2023
30 Jun 2023 report: 34; public on 14 Aug 2023
30 Sep 2023 report: 35; public on 14 Nov 2023
31 Dec 2023 report: 37; public on 14 Feb 2024
31 Mar 2024 report: 53; public on 15 May 2024
30 Jun 2024 report: 75; public on 14 Aug 2024
30 Sep 2024 report: 90; public on 14 Nov 2024
31 Dec 2024 report: 89; public on 14 Feb 2025
31 Mar 2025 report: 125; public on 15 May 2025
30 Jun 2025 report: 112; public on 14 Aug 2025
30 Sep 2025 report: 125; public on 14 Nov 2025
31 Dec 2025 report: 128; public on 17 Feb 2026
31 Mar 2026 report: 145; public on 15 May 2026
30 Jun 2026 report: 157; public on 14 Aug 2026
30 Sep 2026 report: 156; public on 16 Nov 2026
What is unusual now
Made public in the last 90 days: it had 17.1M shares sold short in the 15 Sep 2026 report, 1.7× the same report last year; it also had 16.6M shares sold short in the 14 Aug 2026 report, 1.7× the same report last year. 3 sharp changes in all.
Short interest spike: had 17.0M shares sold short in the 31 Jul 2026 report, 1.7× the same report last year Public on 12 Aug 2026.
Two or more unrelated kinds of records unusual within 30 days
18 Mar 2025confirmed
Confirmed across sources Insiders and Institutional holdings and Short interest and volume
Solid Biosciences(SLDB): had 3 insiders buy $26.1M of its shares on the open market within 30 days (3 filings); it also saw 51 13F filers open a new position in the quarter ended 31 Mar 2025, 2.4× the same quarter last year; and it had 10.2M shares sold short in the 15 Jul 2025 report, 6.2× the same report last year. Three unrelated kinds of activity within 192 days.
Insiders: Clustered insider buying, became public on 22 Feb 2025
Short interest and volume: Short interest spike, became public on 12 Mar 2025
Short interest and volume: Short interest spike, became public on 26 Mar 2025
Short interest and volume: Short interest spike, became public on 10 Apr 2025
Short interest and volume: Short interest spike, became public on 26 Apr 2025
Short interest and volume: Short interest spike, became public on 10 May 2025
Institutional holdings: Many funds opening a new position, became public on 15 May 2025
Short interest and volume: Short interest spike, became public on 28 May 2025
Short interest and volume: Short interest spike, became public on 11 Jun 2025
Short interest and volume: Short interest spike, became public on 26 Jun 2025
Short interest and volume: Short interest spike, became public on 25 Jul 2025
Short interest and volume: Short interest spike, became public on 12 Aug 2025
Short interest and volume: Short interest spike, became public on 27 Aug 2025
The quarter ended 31 Mar 2025 against the 8 quarters before it.
this quarterearliernormal: 9See the evidence (13 changes)
Insiders: Clustered insider buying became public on 22 Feb 2025
Solid Biosciences had 3 insiders buy $26.1M of its shares on the open market within 30 days (3 filings).
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 12 Mar 2025
Solid Biosciences had 7.3M shares sold short in the 28 Feb 2025 report, 12× the same report last year.
This period
7.3M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
505K
How far from its usual level
+7.6
Same report last year
634K
History used
2,585 days
the 28 Feb 2025 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Mar 2025
Solid Biosciences had 7.8M shares sold short in the 14 Mar 2025 report, 13× the same report last year.
This period
7.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
505K
How far from its usual level
+8.3
Same report last year
615K
History used
2,599 days
the 14 Mar 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2025
Solid Biosciences had 8.6M shares sold short in the 31 Mar 2025 report, 9.4× the same report last year.
This period
8.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
505K
How far from its usual level
+9.3
Same report last year
921K
History used
2,616 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Solid Biosciences had 8.1M shares sold short in the 15 Apr 2025 report, 7.7× the same report last year.
This period
8.1M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
488K
How far from its usual level
+8.8
Same report last year
1.0M
History used
2,631 days
the 15 Apr 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2025
Solid Biosciences had 7.1M shares sold short in the 30 Apr 2025 report, 7.8× the same report last year.
This period
7.1M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
468K
How far from its usual level
+7.7
Same report last year
914K
History used
2,646 days
the 30 Apr 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2025
Solid Biosciences saw 51 13F filers open a new position in the quarter ended 31 Mar 2025, 2.4× the same quarter last year.
This period
51 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
6.5
How far from its usual level
+4.4
Same quarter last year
21
History used
2,557 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 9
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 28 May 2025
Solid Biosciences had 9.1M shares sold short in the 15 May 2025 report, 9.7× the same report last year.
This period
9.1M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
453K
How far from its usual level
+10.9
Same report last year
929K
History used
2,661 days
the 15 May 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jun 2025
Solid Biosciences had 8.3M shares sold short in the 30 May 2025 report, 9.9× the same report last year.
This period
8.3M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
432K
How far from its usual level
+10.3
Same report last year
840K
History used
2,676 days
the 30 May 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2025
Solid Biosciences had 8.1M shares sold short in the 13 Jun 2025 report, 8.9× the same report last year.
This period
8.1M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
426K
How far from its usual level
+9.8
Same report last year
904K
History used
2,690 days
the 13 Jun 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2025
Solid Biosciences had 10.2M shares sold short in the 15 Jul 2025 report, 6.2× the same report last year.
This period
10.2M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
661K
How far from its usual level
+8.2
Same report last year
1.7M
History used
2,722 days
the 15 Jul 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Aug 2025
Solid Biosciences had 10.1M shares sold short in the 31 Jul 2025 report, 6.3× the same report last year.
This period
10.1M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
957K
How far from its usual level
+5.4
Same report last year
1.6M
History used
2,738 days
the 31 Jul 2025 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2025
Solid Biosciences had 9.8M shares sold short in the 15 Aug 2025 report, 5.7× the same report last year.
This period
9.8M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+3.6
Same report last year
1.7M
History used
2,753 days
the 15 Aug 2025 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
21 May 2024confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Solid Biosciences(SLDB): saw 21 13F filers open a new position in the quarter ended 31 Mar 2024, 3.0× the same quarter last year, while it had 3.0M shares sold short in the 28 Jun 2024 report, 70× the same report last year. Two unrelated kinds of activity within 77 days.
Short interest and volume: Short interest spike, became public on 25 Apr 2024
Short interest and volume: Short interest spike, became public on 10 May 2024
Institutional holdings: Many funds opening a new position, became public on 15 May 2024
Short interest and volume: Short interest spike, became public on 25 May 2024
Short interest and volume: Short interest spike, became public on 12 Jun 2024
Short interest and volume: Short interest spike, became public on 11 Jul 2024
The quarter ended 31 Mar 2024 against the 8 quarters before it.
this quarterearliernormal: 6.5See the evidence (6 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2024
Solid Biosciences had 1.0M shares sold short in the 15 Apr 2024 report, 23× the same report last year.
This period
1.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
13K
How far from its usual level
+20.1
Same report last year
45K
History used
2,266 days
the 15 Apr 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2024
Solid Biosciences had 914K shares sold short in the 30 Apr 2024 report, 24× the same report last year.
This period
914K (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
15K
How far from its usual level
+17.4
Same report last year
39K
History used
2,281 days
the 30 Apr 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
Solid Biosciences saw 21 13F filers open a new position in the quarter ended 31 Mar 2024, 3.0× the same quarter last year.
This period
21 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.8
Same quarter last year
7
History used
2,192 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
Solid Biosciences had 929K shares sold short in the 15 May 2024 report, 23× the same report last year.
This period
929K (the 15 May 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
20K
How far from its usual level
+17.7
Same report last year
41K
History used
2,296 days
the 15 May 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
Solid Biosciences had 840K shares sold short in the 31 May 2024 report, 33× the same report last year.
This period
840K (the 31 May 2024 report)
Normal report (median of 24 earlier)
124K
Typical spread (median absolute deviation)
96K
How far from its usual level
+5.0
Same report last year
26K
History used
2,312 days
the 31 May 2024 report24 earlier reportsnormal: 124K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jul 2024
Solid Biosciences had 3.0M shares sold short in the 28 Jun 2024 report, 70× the same report last year.
This period
3.0M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
233K
Typical spread (median absolute deviation)
203K
How far from its usual level
+9.4
Same report last year
44K
History used
2,340 days
the 28 Jun 2024 report24 earlier reportsnormal: 233K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
25 Sep 2026Short interest and volume change
had 17.1M shares sold short in the 15 Sep 2026 report, 1.7× the same report last year.
Same report last year: 9.9M; its normal report is 9.8M.
See the evidence
This period
17.1M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
558K
How far from its usual level
+7.4
Same report last year
9.9M
History used
3,149 days
the 15 Sep 2026 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.4M shares sold short in the 31 Aug 2026 report, 1.7× the same report last year.
Same report last year: 9.8M; its normal report is 9.8M.
See the evidence
This period
16.4M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
378K
How far from its usual level
+6.7
Same report last year
9.8M
History used
3,134 days
the 31 Aug 2026 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.6M shares sold short in the 14 Aug 2026 report, 1.7× the same report last year.
Same report last year: 9.8M; its normal report is 9.8M.
See the evidence
This period
16.6M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
333K
How far from its usual level
+7.0
Same report last year
9.8M
History used
3,117 days
the 14 Aug 2026 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 17.0M shares sold short in the 31 Jul 2026 report, 1.7× the same report last year.
Same report last year: 10.1M; its normal report is 9.8M.
See the evidence
This period
17.0M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
333K
How far from its usual level
+7.4
Same report last year
10.1M
History used
3,103 days
the 31 Jul 2026 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.8M shares sold short in the 15 Aug 2025 report, 5.7× the same report last year.
Same report last year: 1.7M; its normal report is 2.8M.
See the evidence
This period
9.8M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+3.6
Same report last year
1.7M
History used
2,753 days
the 15 Aug 2025 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.1M shares sold short in the 31 Jul 2025 report, 6.3× the same report last year.
Same report last year: 1.6M; its normal report is 2.5M.
See the evidence
This period
10.1M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
957K
How far from its usual level
+5.4
Same report last year
1.6M
History used
2,738 days
the 31 Jul 2025 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.2M shares sold short in the 15 Jul 2025 report, 6.2× the same report last year.
Same report last year: 1.7M; its normal report is 2.2M.
See the evidence
This period
10.2M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
661K
How far from its usual level
+8.2
Same report last year
1.7M
History used
2,722 days
the 15 Jul 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.1M shares sold short in the 13 Jun 2025 report, 8.9× the same report last year.
Same report last year: 904K; its normal report is 1.9M.
See the evidence
This period
8.1M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
426K
How far from its usual level
+9.8
Same report last year
904K
History used
2,690 days
the 13 Jun 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.3M shares sold short in the 30 May 2025 report, 9.9× the same report last year.
Same report last year: 840K; its normal report is 1.8M.
See the evidence
This period
8.3M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
432K
How far from its usual level
+10.3
Same report last year
840K
History used
2,676 days
the 30 May 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.1M shares sold short in the 15 May 2025 report, 9.7× the same report last year.
Same report last year: 929K; its normal report is 1.7M.
See the evidence
This period
9.1M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
453K
How far from its usual level
+10.9
Same report last year
929K
History used
2,661 days
the 15 May 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 51 13F filers open a new position in the quarter ended 31 Mar 2025, 2.4× the same quarter last year.
Same quarter last year: 21; its normal quarter is 9.
See the evidence
This period
51 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
6.5
How far from its usual level
+4.4
Same quarter last year
21
History used
2,557 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 9
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 7.1M shares sold short in the 30 Apr 2025 report, 7.8× the same report last year.
Same report last year: 914K; its normal report is 1.7M.
See the evidence
This period
7.1M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
468K
How far from its usual level
+7.7
Same report last year
914K
History used
2,646 days
the 30 Apr 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.1M shares sold short in the 15 Apr 2025 report, 7.7× the same report last year.
Same report last year: 1.0M; its normal report is 1.7M.
See the evidence
This period
8.1M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
488K
How far from its usual level
+8.8
Same report last year
1.0M
History used
2,631 days
the 15 Apr 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.6M shares sold short in the 31 Mar 2025 report, 9.4× the same report last year.
Same report last year: 921K; its normal report is 1.7M.
See the evidence
This period
8.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
505K
How far from its usual level
+9.3
Same report last year
921K
History used
2,616 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.8M shares sold short in the 14 Mar 2025 report, 13× the same report last year.
Same report last year: 615K; its normal report is 1.7M.
See the evidence
This period
7.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
505K
How far from its usual level
+8.3
Same report last year
615K
History used
2,599 days
the 14 Mar 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3 insiders buy $26.1M of its shares on the open market within 30 days (3 filings); it also saw 51 13F filers open a new position in the quarter ended 31 Mar 2025, 2.4× the same quarter last year; and it had 10.2M shares sold short in the 15 Jul 2025 report, 6.2× the same report last year. Three unrelated kinds of activity within 192 days.
See the evidence (13 changes)
Insiders: Clustered insider buying became public on 22 Feb 2025
Solid Biosciences had 3 insiders buy $26.1M of its shares on the open market within 30 days (3 filings).
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 12 Mar 2025
Solid Biosciences had 7.3M shares sold short in the 28 Feb 2025 report, 12× the same report last year.
This period
7.3M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
505K
How far from its usual level
+7.6
Same report last year
634K
History used
2,585 days
the 28 Feb 2025 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Mar 2025
Solid Biosciences had 7.8M shares sold short in the 14 Mar 2025 report, 13× the same report last year.
This period
7.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
505K
How far from its usual level
+8.3
Same report last year
615K
History used
2,599 days
the 14 Mar 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2025
Solid Biosciences had 8.6M shares sold short in the 31 Mar 2025 report, 9.4× the same report last year.
This period
8.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
505K
How far from its usual level
+9.3
Same report last year
921K
History used
2,616 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Solid Biosciences had 8.1M shares sold short in the 15 Apr 2025 report, 7.7× the same report last year.
This period
8.1M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
488K
How far from its usual level
+8.8
Same report last year
1.0M
History used
2,631 days
the 15 Apr 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2025
Solid Biosciences had 7.1M shares sold short in the 30 Apr 2025 report, 7.8× the same report last year.
This period
7.1M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
468K
How far from its usual level
+7.7
Same report last year
914K
History used
2,646 days
the 30 Apr 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2025
Solid Biosciences saw 51 13F filers open a new position in the quarter ended 31 Mar 2025, 2.4× the same quarter last year.
This period
51 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
6.5
How far from its usual level
+4.4
Same quarter last year
21
History used
2,557 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 9
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 28 May 2025
Solid Biosciences had 9.1M shares sold short in the 15 May 2025 report, 9.7× the same report last year.
This period
9.1M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
453K
How far from its usual level
+10.9
Same report last year
929K
History used
2,661 days
the 15 May 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jun 2025
Solid Biosciences had 8.3M shares sold short in the 30 May 2025 report, 9.9× the same report last year.
This period
8.3M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
432K
How far from its usual level
+10.3
Same report last year
840K
History used
2,676 days
the 30 May 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2025
Solid Biosciences had 8.1M shares sold short in the 13 Jun 2025 report, 8.9× the same report last year.
This period
8.1M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
426K
How far from its usual level
+9.8
Same report last year
904K
History used
2,690 days
the 13 Jun 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2025
Solid Biosciences had 10.2M shares sold short in the 15 Jul 2025 report, 6.2× the same report last year.
This period
10.2M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
661K
How far from its usual level
+8.2
Same report last year
1.7M
History used
2,722 days
the 15 Jul 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Aug 2025
Solid Biosciences had 10.1M shares sold short in the 31 Jul 2025 report, 6.3× the same report last year.
This period
10.1M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
957K
How far from its usual level
+5.4
Same report last year
1.6M
History used
2,738 days
the 31 Jul 2025 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2025
Solid Biosciences had 9.8M shares sold short in the 15 Aug 2025 report, 5.7× the same report last year.
This period
9.8M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+3.6
Same report last year
1.7M
History used
2,753 days
the 15 Aug 2025 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
had 7.3M shares sold short in the 28 Feb 2025 report, 12× the same report last year.
Same report last year: 634K; its normal report is 1.6M.
See the evidence
This period
7.3M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
505K
How far from its usual level
+7.6
Same report last year
634K
History used
2,585 days
the 28 Feb 2025 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
saw 23 13F filers open a new position in the quarter ended 30 Sep 2024, 7.7× the same quarter last year.
Same quarter last year: 3; its normal quarter is 6.5.
See the evidence
This period
23 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
3
How far from its usual level
+3.7
Same quarter last year
3
History used
2,375 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 27 13F filers open a new position in the quarter ended 30 Jun 2024, 14× the same quarter last year.
Same quarter last year: 2; its normal quarter is 6.5.
See the evidence
This period
27 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
3
How far from its usual level
+4.6
Same quarter last year
2
History used
2,283 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 3.0M shares sold short in the 28 Jun 2024 report, 70× the same report last year.
Same report last year: 44K; its normal report is 233K.
See the evidence
This period
3.0M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
233K
Typical spread (median absolute deviation)
203K
How far from its usual level
+9.4
Same report last year
44K
History used
2,340 days
the 28 Jun 2024 report24 earlier reportsnormal: 233K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 840K shares sold short in the 31 May 2024 report, 33× the same report last year.
Same report last year: 26K; its normal report is 124K.
See the evidence
This period
840K (the 31 May 2024 report)
Normal report (median of 24 earlier)
124K
Typical spread (median absolute deviation)
96K
How far from its usual level
+5.0
Same report last year
26K
History used
2,312 days
the 31 May 2024 report24 earlier reportsnormal: 124K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 929K shares sold short in the 15 May 2024 report, 23× the same report last year.
Same report last year: 41K; its normal report is 43K.
See the evidence
This period
929K (the 15 May 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
20K
How far from its usual level
+17.7
Same report last year
41K
History used
2,296 days
the 15 May 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 21 13F filers open a new position in the quarter ended 31 Mar 2024, 3.0× the same quarter last year, while it had 3.0M shares sold short in the 28 Jun 2024 report, 70× the same report last year. Two unrelated kinds of activity within 77 days.
See the evidence (6 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2024
Solid Biosciences had 1.0M shares sold short in the 15 Apr 2024 report, 23× the same report last year.
This period
1.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
13K
How far from its usual level
+20.1
Same report last year
45K
History used
2,266 days
the 15 Apr 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2024
Solid Biosciences had 914K shares sold short in the 30 Apr 2024 report, 24× the same report last year.
This period
914K (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
15K
How far from its usual level
+17.4
Same report last year
39K
History used
2,281 days
the 30 Apr 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
Solid Biosciences saw 21 13F filers open a new position in the quarter ended 31 Mar 2024, 3.0× the same quarter last year.
This period
21 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.8
Same quarter last year
7
History used
2,192 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
Solid Biosciences had 929K shares sold short in the 15 May 2024 report, 23× the same report last year.
This period
929K (the 15 May 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
20K
How far from its usual level
+17.7
Same report last year
41K
History used
2,296 days
the 15 May 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
Solid Biosciences had 840K shares sold short in the 31 May 2024 report, 33× the same report last year.
This period
840K (the 31 May 2024 report)
Normal report (median of 24 earlier)
124K
Typical spread (median absolute deviation)
96K
How far from its usual level
+5.0
Same report last year
26K
History used
2,312 days
the 31 May 2024 report24 earlier reportsnormal: 124K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jul 2024
Solid Biosciences had 3.0M shares sold short in the 28 Jun 2024 report, 70× the same report last year.
This period
3.0M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
233K
Typical spread (median absolute deviation)
203K
How far from its usual level
+9.4
Same report last year
44K
History used
2,340 days
the 28 Jun 2024 report24 earlier reportsnormal: 233K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2024Institutional holdings change
saw 21 13F filers open a new position in the quarter ended 31 Mar 2024, 3.0× the same quarter last year.
Same quarter last year: 7; its normal quarter is 6.5.
See the evidence
This period
21 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.8
Same quarter last year
7
History used
2,192 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 914K shares sold short in the 30 Apr 2024 report, 24× the same report last year.
Same report last year: 39K; its normal report is 43K.
See the evidence
This period
914K (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
15K
How far from its usual level
+17.4
Same report last year
39K
History used
2,281 days
the 30 Apr 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.0M shares sold short in the 15 Apr 2024 report, 23× the same report last year.
Same report last year: 45K; its normal report is 43K.
See the evidence
This period
1.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
43K
Typical spread (median absolute deviation)
13K
How far from its usual level
+20.1
Same report last year
45K
History used
2,266 days
the 15 Apr 2024 report24 earlier reportsnormal: 43K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 921K shares sold short in the 28 Mar 2024 report, 25× the same report last year.
Same report last year: 36K; its normal report is 42K.
See the evidence
This period
921K (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
42K
Typical spread (median absolute deviation)
12K
How far from its usual level
+17.6
Same report last year
36K
History used
2,248 days
the 28 Mar 2024 report24 earlier reportsnormal: 42K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 615K shares sold short in the 15 Mar 2024 report, 29× the same report last year.
Same report last year: 21K; its normal report is 41K.
See the evidence
This period
615K (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
41K
Typical spread (median absolute deviation)
11K
How far from its usual level
+11.5
Same report last year
21K
History used
2,235 days
the 15 Mar 2024 report24 earlier reportsnormal: 41K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 92 entries; narrow the window or the kind of data to see older ones.
Not listed: 182 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it